UPDATE: Cowen Starts Burning Rock Biotech Ltd. (BNR) at Outperform

July 7, 2020 5:33 AM EDT
Get Alerts BNR Hot Sheet
Price: $20.37 +0.69%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 13 | New: 22
Trade Now! 
Join SI Premium – FREE
(Updated - July 7, 2020 6:29 AM EDT)

(updated to add analyst comments)

Cowen analyst Doug Schenkel initiates coverage on Burning Rock Biotech Ltd. (NASDAQ: BNR) with an Outperform rating.

The analyst commented, "Burning Rock has an early “first mover” advantage in the Chinese cancer profiling market. The company is pursuing a dual-pronged commercial strategy that leverages unique chemistry/assays to drive growth and increase market adoption in a large multibillion-dollar market. Biopharma and US-based Tools partners serve as known validation of the company’s approach and prowess. Initiate Outperform."

For an analyst ratings summary and ratings history on Burning Rock Biotech Ltd. click here. For more ratings news on Burning Rock Biotech Ltd. click here.

Shares of Burning Rock Biotech Ltd. closed at $26.50 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Cowen & Co